Healthcare >> CEO Interviews >> December 2, 1999

Scott M. Rocklage – Cubist Pharmaceuticals Inc (cbst)

SCOTT M. ROCKLAGE currently serves as Chairman and CEO of Cubist Pharmaceuticals, Inc. Dr. Rocklage was elected Chairman of the Board of Directors in March 2000. He has served as Chief Executive Officer and as a member of the Board of Directors of Cubist Pharmaceuticals since July 1994. Dr. Rocklage also served as Cubist's President from July 1994 until March 2001. From 1990 to 1994, Dr. Rocklage served as President and Chief Executive Officer of Nycomed Salutar, Inc., a diagnostic imaging company and from 1992 to 1994, he also served as Chairman, President and Chief Executive Officer of Nycomed Interventional, Inc., a medical device company. From 1986 to 1990, he served in various positions at Nycomed Salutar, Inc., and was responsible for designing and implementing research and development programs that resulted in three drug products in human clinical trials, including the approved drugs Omniscan and Teslascan. Dr. Rocklage has also served as a director of MDS Proteomics, Inc., since July 2001. He received his BS in Chemistry from the University of California, Berkeley, and his PhD in Chemistry from the Massachusetts Institute of Technology. Profile
TWST: Give us a brief overview of Cubist Pharmaceuticals, Inc.?

Dr. Rocklage: Cubist's mission is based on the discovery of novel

antiinfectives to treat serious and life-threatening